Gan & Lee Pharmaceuticals Co Ltd (603087 SHG) stock market data APIs
¥56.9934
1.55(2.7%)
as of May 14, 2026
Try our APIs with
free plan!
Gan & Lee Pharmaceuticals Co Ltd Financial Data Overview
Price chart is built with
Anychart
Gan & Lee Pharmaceuticals., a biopharmaceutical company, engages in the research, development, production, and sale of insulin analog active pharmaceutical ingredients (APIs) and injections in China. Its products include Basalin, an insulin glargine injection; Prandilin, an insulin lispro injection; Prandilin 25, an insulin lispro mix 75/25 injection; Rapilin, an insulin aspart injection; Rapilin 30, an insulin aspart 30 injection; and Similin 30, a mixed protamine human insulin injection. The company also offers GanleePen, an insulin injection device; GanleeFine, an insulin pen needle; and other medical devices. The company was formerly known as Beijing Gan & Lee Biotechnology Co., Ltd. and changed its name to Gan & Lee Pharmaceuticals. in April 2005. Gan & Lee Pharmaceuticals. was founded in 1998 and is headquartered in Beijing, the People's Republic of China.
Prev. Close
56.9934
Open
58.5419
High
58.7591
Low
56.9445
52 wk Range
49.97-82.25
Market Cap
34 823 M
P/E Ratio
33.6994
Shares Outstanding
597 M
Revenue
3 945 M
EPS
0.55
Dividends (Yield)
0.0169
Beta
0.566
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Gan & Lee Pharmaceuticals Co Ltd (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Gan & Lee Pharmaceuticals Co Ltd data using free add-ons & libraries
Get Gan & Lee Pharmaceuticals Co Ltd Fundamental Data
Gan & Lee Pharmaceuticals Co Ltd Fundamental data includes:
- Net Revenue: 3 945 M
- EBITDA: 1 036 M
- Earnings Per Share: 1
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
Get Gan & Lee Pharmaceuticals Co Ltd Earnings data
Corporate Events Calendar & News package for
$
19.99
/mo.
What’s included:
- Latest Release: 2026-04-22
- EPS/Forecast: 0.45
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Gan & Lee Pharmaceuticals Co Ltd News
New
Semaglutide Preparations Market - Global Forecast 2025-2030 Featuring Novo Nordisk, Gan & Lee Pharmaceuticals, Shanghai Fosun Pharmaceutical, and Luye Pharmaceutical
Company Logo Emerging opportunities include advancing semaglutide in type 2 diabetes and obesity treatment, focusing on oral and injectable forms, biosimilar competition, digital adherence solutions,...
Gan & Lee Pharmaceuticals Announced First Participant Dosed in the US Phase 2 Clinical Study of Bofanglutide (GZR18) Injection for Overweight or Obesity
BEIJING and BRIDGEWATER, N.J., March 10, 2025 /PRNewswire/ -- Gan & Lee Pharmaceuticals (Gan & Lee, Shanghai Stock Exchange: 603087) announced that the first participant has been successfully dosed in...
Gan & Lee Pharmaceuticals Announces U.S. FDA Clearance of the IND application for the innovative Bi-weekly GLP-1RA GZR18 Injection, Bofanglutide, with chronic weight management Indication (A Phase 2 head-to-head with Tirzepatide clinical trial)
BEIJING and BRIDGEWATER, N.J., Dec. 18, 2024 /PRNewswire/ -- Gan & Lee Pharmaceuticals (Gan & Lee, Shanghai Stock Exchange: 603087.SH), is pleased to announce that the Food and Drug Administration ("...
Gan & Lee Pharmaceuticals Announced Positive Phase 1 Results for Its Oral GLP-1 Receptor Agonist GZR18 Tablet in Healthy Participants, Demonstrating 4.16% Weight Reduction in Two Weeks
After two weeks of treatment, GZR18 tablets resulted in an average weight reduction of up to 4.16%, with continued weight loss observed even after discontinuation. The pharmacokinetic profile support...
Get Gan & Lee Pharmaceuticals Co Ltd fresh news feed via Financial News API
Corporate Events Calendar & News package for
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
